Previous 10 | Next 10 |
Every year it seems like the cost of healthcare just goes up. Even as standards of care get better, it often comes with more cost to the patient. But every once in a while there's a disruptive technology that turns that equation on its head. DermTech (NASDAQ: DMTK) is one of those c...
DermTech, Inc. (NASDAQ: DMTK) (“DermTech”), a leader in precision dermatology enabled by a non-invasive skin genomics platform, announced today the appointment of Monica Tellado, Senior Vice President, Finance at Gilead Sciences to its Board of Directors. “W...
DermTech , Inc. (NASDAQ: DMTK) (“DermTech”), a leader in precision dermatology enabled by a non-invasive skin genomics platform, announced today that DermTech CEO, John Dobak, M.D., has been selected as a winner for the San Diego Business Journal CEO of the Year Awards...
DermTech (DMTK) announces a collaboration with researchers from the University of Barcelona to investigate the modulatory effect of targeted therapies in models of inflammatory skin disease.The research study will use DermTech’s Smart Sticker-enabled platform to interrogate inflam...
DermTech , Inc. (NASDAQ: DMTK) (“DermTech”), a leader in precision dermatology enabled by a non-invasive skin genomics platform, announced today a collaboration with researchers from the University of Barcelona, led by lead investigator Dr. Luis F Santamaria-Babí,...
DMTK markets skin cancer diagnostics products. It has one approved diagnostics, the PLA test, and more in pipeline. Various studies have shown that the PLA test is much more accurate than traditional visual tests. For further details see: DermTech: Revolutionizing The Sk...
DermTech has created a patch to disrupt the skin cancer detection market. The patch is placed on the skin for a few seconds to collect RNA. Currently, they are only working to fight melanoma and skin cancer, but they are also trying to slowly expand into new types of skin cancer. ...
ersinkisacik/iStock via Getty Images DermTech (DMTK) has named Loren Clarke as the company’s new chief medical officer replacing Burkhard Jansen who has taken on a new role as chief medical affairs officer, the company said. Clarke joins DermTech from Myriad Genetics where he served as...
DermTech, Inc. (NASDAQ: DMTK) (“DermTech”), a leader in precision dermatology enabled by a non-invasive skin genomics platform, announced today three new key leadership appointments: Loren Clarke, M.D. to the role of Chief Medical Officer, Ray Bassi to the role of Vice Pre...
PAVmed's main commercial-stage product, EsoCheck/EsoGuard, is a life-saving product addressing a $25bil market and is supported by Exact Sciences founder Stanley Lapidus. PAVmed's second commercial-stage product, CarpX, is a minimally invasive tool to conduct carpel tunnel surgery and...